10-Q: Disc Medicine Reports Q1 2026 Financials, Bitopertin NDA Update

Disc Medicine Inc. reported its Q1 2026 financial results, highlighting increased R&D expenses and providing an update on the bitopertin New Drug Application (NDA) status.

Summary

• Disc Medicine, Inc. filed its Form 10-Q for the quarterly period ended March 31, 2026.
• The company reported a net loss of $63.5 million for the three months ended March 31, 2026, compared to a net loss of $34.1 million for the same period in 2025.
• Research and development expenses increased significantly to $45.9 million from $27.8 million year-over-year, primarily due to increased spending on DISC-3405 and personnel-related costs.
• Selling, general, and administrative expenses also rose to $23.6 million from $12.2 million, driven by increased headcount and stock-based compensation.
• As of March 31, 2026, the company had cash, cash equivalents, and marketable securities totaling $730.2 million, which management believes is sufficient to fund operations into 2029.
• The company received a Complete Response Letter (CRL) from the FDA for its bitopertin NDA in February 2026, stating that the submitted data did not sufficiently demonstrate the association between PPIX reduction and sunlight exposure endpoints.
• Disc Medicine plans to resubmit its NDA following topline data from the ongoing APOLLO Phase 3 trial, with an anticipated FDA decision by mid-2027.
• The company initiated a Phase 2 clinical trial for DISC-0974 in patients with IBD and anemia in Q1 2026.
• DISC-3405 trial data presented in June 2025 showed dose-related increases in serum hepcidin and reductions in serum iron.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the increased net loss and the significant setback with the bitopertin NDA, despite the company's strong cash position.

Positives

• The company maintains a strong liquidity position with $730.2 million in cash, cash equivalents, and marketable securities as of March 31, 2026, expected to fund operations into 2029.
• The FDA agreed that clinical data from AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers whole blood metal-free PPIX.
• Interim data from the HELIOS extension study showed sustained reductions in PPIX and improvements in quality of life and liver biomarkers with longer-term bitopertin treatment.
• The company received a Commissioners National Priority Voucher (CNPV) for bitopertin, although its benefit in the current regulatory context is unclear.
• DISC-0974 has shown substantial and sustained reductions in hepcidin levels and increases in iron in Phase 1b trials for anemia of MF.
• DISC-3405 has demonstrated an acceptable tolerability profile and evidence of target engagement, including dose-related increases in serum hepcidin and corresponding reductions in serum iron in Phase 1 trials.

Negatives

• The company reported a net loss of $63.5 million for Q1 2026, an increase from $34.1 million in Q1 2025.
• Research and development expenses increased by $18.1 million year-over-year, driven by higher spending on DISC-3405 and personnel costs.
• Selling, general, and administrative expenses increased by $11.4 million year-over-year, primarily due to personnel costs and stock-based compensation.
• The FDA issued a Complete Response Letter (CRL) for the bitopertin NDA, indicating that the submitted data did not sufficiently predict clinical benefit.
• The company expects to resubmit the bitopertin NDA by mid-2027, delaying potential commercialization.
• The company has no products approved for commercial sale and has not generated any revenue from product sales.

Risks

• The company has a limited operating history and has incurred significant net losses since inception, with no products approved for commercial sale.
• The company may need to raise substantial additional funding, and failure to do so could force delays or elimination of product development programs.
• Clinical trials may not be successful, and results from early studies may not be predictive of later-stage results.
• The FDA's CRL for bitopertin highlights uncertainty regarding the prediction of clinical benefit from PPIX reduction, requiring further confirmatory trials.
• The company faces substantial competition in the hematologic disease therapeutic area.
• Reliance on third parties for clinical trials and manufacturing introduces risks of delays and non-compliance.
• Intellectual property protection is crucial, and challenges to patents or failure to obtain broad protection could impair commercialization.
• The company's future success depends on its ability to retain key personnel and attract qualified talent.
• The market price of the company's common stock has been and may continue to be volatile.
• The company's existing and any future indebtedness could adversely affect its ability to operate its business.

Future Outlook

The company believes its current cash, cash equivalents, and marketable securities of $730.2 million will be sufficient to fund its planned operating expenses and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements, and potentially into 2029. The company expects operating losses and negative operating cash flows to continue into the foreseeable future. The company plans to resubmit its NDA for bitopertin following topline data from the APOLLO trial, with an anticipated FDA decision by mid-2027.

Management Comments

• We believe that each of our product candidates, if approved, has the potential to improve the lives of patients suffering from hematologic diseases.
• We believe that our cash, cash equivalents and marketable securities will be sufficient to fund our current operating and capital expenditure plans and our debt service obligations into 2029, without taking into account any potential net cash inflows from bitopertin or any other marketed product, if approved during such period.

Industry Context

StockSavvy.ai notes that Disc Medicine operates in the highly competitive biopharmaceutical sector, focusing on hematologic diseases. The company's progress with bitopertin, despite the FDA's CRL, and its ongoing development of DISC-0974 and DISC-3405, align with industry trends of targeting specific pathways for rare and serious diseases. The significant increase in R&D spending is typical for clinical-stage biotechs advancing multiple candidates.

Legal Proceedings

• The company was not subject to any material legal proceedings during the three months ended March 31, 2026 and 2025, and to the best of its knowledge, no material legal proceedings are currently pending or threatened.

Related Party Transactions

• In October 2025 and January 2025, certain existing investors participated in the Company's underwritten offerings.

Stakeholder Impact

• Shareholders may experience continued stock price volatility due to the FDA's CRL for bitopertin and increased operating expenses.
• Employees may face uncertainty due to increased R&D spending and the need for future funding, although the company's cash position provides some stability.
• Patients awaiting potential treatments for hematologic diseases face continued delays in the availability of bitopertin.

Next Steps

• Resubmit NDA for bitopertin following topline data from the APOLLO trial.
• Anticipate FDA decision on bitopertin NDA by mid-2027.
• Report updated data from the RALLY-MF trial in June 2026.
• Report topline data from the RALLY-MF trial in Q4 2026.
• Hold end-of-Phase 2 meeting with the FDA for DISC-0974 in anemia of MF by the end of 2026.
• Report initial data from the Phase 2 clinical trial of DISC-0974 in IBD and anemia in 2027.
• Report initial data from the RESTORE-PV trial of DISC-3405 in Q4 2026.
• Report initial data from the Phase 1b clinical trial of DISC-3405 in SCD in Q4 2026.
• Schedule a Type A meeting with the FDA during Q2 2026 to review the approach for resubmitting the bitopertin NDA.

Key Dates

Recommendation

While the company has a strong cash position and promising pipeline candidates, the FDA's CRL for bitopertin represents a significant setback and delays potential revenue generation. The increased R&D spending, while necessary for development, also contributes to a widening net loss. Investors should monitor the progress of the APOLLO trial and the resubmission of the bitopertin NDA, as well as the development of DISC-0974 and DISC-3405, before considering a more aggressive stance.

Keywords

Disc Medicine, 10-Q, Biopharmaceutical, Hematologic Diseases, Bitopertin, EPP, XLP, DISC-0974, DISC-3405, Clinical Trials, FDA, NDA, CRL, Research and Development, Financial Results